Etude : TrilynX / Debio 1143-SCCHN-301



ATTENTION : pour chaque essai clinique, les éléments affichés ci-dessous ne sont pas exhaustifs, et le protocole fourni par le promoteur reste l’unique document à consulter pour mener à bien un essai clinique sur centre. Pour plus d'informations, contactez le référent du territoire concerné.


Acronyme / Nom
Situation thérapeutique
Traitement
Cadre réglementaire
MÀJ
Présentation de l'étude
Acronyme / Nom : TrilynX / Debio 1143-SCCHN-301

Situation thérapeutique : Métastatique ou localement avancé

Traitement : Chimiothérapie / Thérapie ciblée / Radiothérapie

Cadre réglementaire : RIPH1

Dernière MÀJ : 30/11/2021
Titre
Spécialité(s)
CIM10 - Localisation(s)
Informations principales
Titre : Etude de phase 3, randomisée, en double aveugle, contrôlée par placebo, portant sur Debio 1143 associé à une chimiothérapie à base de platine et une radiothérapie concomitante conformationnelle par modulation d’intensité chez les patients atteints d’un carcinome épidermoïde à cellules squameuses de la tête et du cou localement avancé (LA-SCCHN), pour lequel une chimioradiothérapie définitive est appropriée

Spécialité : Lèvre, cavité buccale et pharynx
Localisation : C00 - Tumeur maligne de la lèvre

Spécialité : Organes respiratoires et intrathoraciques
Localisation : C32 - Tumeur maligne du larynx

Spécialité : Lèvre, cavité buccale et pharynx
Localisation : C01 - Tumeur maligne de la base de la langue

Spécialité : Lèvre, cavité buccale et pharynx
Localisation : C03 - Tumeur maligne de la gencive

Spécialité : Lèvre, cavité buccale et pharynx
Localisation : C04 - Tumeur maligne du plancher de la bouche

Spécialité : Lèvre, cavité buccale et pharynx
Localisation : C05 - Tumeur maligne du palais

Spécialité : Lèvre, cavité buccale et pharynx
Localisation : C14 - Tumeur maligne de la lèvre, de la cavité buccale et du pharynx, de sièges autres et mal définis

Spécialité : Lèvre, cavité buccale et pharynx
Localisation : C09 - Tumeur maligne de l'amygdale

Spécialité : Lèvre, cavité buccale et pharynx
Localisation : C10 - Tumeur maligne de l'oropharynx

Spécialité : Lèvre, cavité buccale et pharynx
Localisation : C02 - Tumeur maligne de la langue, parties autres et non précisées

Spécialité : Lèvre, cavité buccale et pharynx
Localisation : C13 - Tumeur maligne de l'hypopharynx
Schéma
Phase
Stade
Ligne(s)
Informations complémentaires
Schéma : L'essai clinique TrilynX évalue un médicament expérimental, Debio 1143, afin de voir s'il peut optimiser l’efficacité de la chimioradiothérapie (CRT) lorsqu'ils sont administrés ensemble. Tous les patients recevront une CRT à base de platine ; en outre, ils seront randomisés selon un rapport de 1:1 afin de recevoir Debio 1143 ou le placebo.

STUDY ARMS:
- Experimental: Debio 1143
Concomitant chemo-radiation therapy period (Cycles 1-3) + monotherapy period (Cycles 4-6):

- Active Comparator: Placebo
Concomitant chemo-radiation therapy period (Cycles 1-3) + Monotherapy period (Cycles 4-6):

MAIN OBJECTIVE:
To demonstrate superior efficacy of Debio 1143 vs placebo when added to CRT in locally advanced SCCHN

SECONDARY OBJECTIVES:
- To assess the efficacy of Debio 1143 compared to placebo when added to CRT according to additional efficacy endpoints.
- To compare safety, tolerability and treatment compliance of Debio 1143 vs placebo, when added to CRT.
- To compare the health-related quality of life of Debio 1143 vs placebo when added to CRT using patient-reported outcome questionnaires.

Phase : III

Stade : Localement avancé

1
Informations libres de droit
Critères d'inclusion
Critères de non-inclusion
Informations libres de droit
Critères d'inclusion et de non-inclusion
Critères d'inclusion : 1. Willing and able to sign written informed consent prior to study screening.
2. Male or female ≥ 18 years of age (or based on the country legal age limit for adults) on day of signing the ICF.
3. Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.
4. Histologically confirmed diagnosis in previously untreated LA-SCCHN patient (stage III, IVA or IVB according to the American Joint Committee on Cancer [AJCC]/TNM Staging System, 8th Ed.) suitable for definitive CRT as defined in the protocol.
5. Evaluable tumor burden (measurable and/or non-measurable tumor lesions) assessed by computed tomography scan (CT-scan) or magnetic resonance imaging (MRI), based on RECIST v 1.1.
6. For OPC patients, primary tumors must be HPV-negative as determined by p16 expression using immunohistochemistry (IHC).
7. Able to swallow liquids or has an adequately functioning feeding tube, gastrostomy or jejunostomy placed.
8. No hearing loss by clinical assessment.
9. Peripheral neuropathy < grade 2
10. Adequate hematologic, renal and hepatic function as defined in the protocol.
11. Women of childbearing potential (according to recommendations of the Clinical Trial Facilitation Group) must have a negative serum pregnancy test at screening and must not be breastfeeding. Non-sterilized males who are sexually active with a female partner of childbearing potential must agree to use adequate birth control as defined in the protocol from ICF signature to 6 months after the last administration of chemotherapy or 3 months after the last dose of Debio 1143/matched placebo, whichever is the latest.

Critères de non-inclusion : 1. Primary tumor of nasopharyngeal, paranasal sinuses, nasal or oral cavity, salivary, thyroid or parathyroid gland pathologies, skin or unknown primary site.
2. Metastatic disease (stage IVC as per AJCC/TNM, 8th Ed.).
3. Prior definitive or adjuvant RT and/or radical surgery to the head and neck region which may jeopardize the primary tumor irradiation plan, or any other prior SCCHN systemic treatment, including investigational agents.
4. Use within 14 days prior to randomization or requirement for ongoing treatment with any drug(s) on the prohibited medication list.
5. Treatment with an investigational agent or use of an investigational device within 4 weeks of the first dose of study treatment.
6. Known history of infection with HIV. If unknown history of HIV, an HIV screening test is to be performed and subjects with positive serology for HIV-1/2 must be excluded.
7. Known chronically active HBV or HCV infection. If unknown status, see further details in the protocol.
8. Other infections (viral and/or bacterial and/or mycotic) requiring systemic treatment.
9. Live-attenuated vaccinations within 30 days prior to first investigational treatment administration.
10. Ongoing uncontrolled infection requiring intravenous antibiotic therapy within 1 week prior to randomization.
11. Known gastrointestinal disorder with clinically established malabsorption syndrome and major gastrointestinal surgery that may limit oral absorption.
12. Documented weight loss of >10% during the last 4 weeks prior to randomization (unless adequate measures are undertaken for nutritional support), OR plasmatic albumin <3.0 g/dL.
13. Active gastrointestinal bleeding, or any other uncontrolled bleeding requiring more than 2 red blood cell transfusions or 4 units of packed red blood cells within 4 weeks prior to randomization.
14. Active uncontrolled inflammatory disease (including rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome, severe extensive psoriasis) requiring ongoing treatment with anti-TNF medication.
15. Any concomitant medication known to prolong the QT interval that cannot be discontinued or replaced by safe alternative medication within 7 days prior to start of treatment.
16. Impaired cardiovascular function or clinically significant cardiovascular diseases, see further details in the protocol.
17. Symptomatic pulmonary disease requiring continuous or intermittent oxygen supply.
18. History of another malignancy within the last 3 years prior to randomization, with the exception of completely resected non-melanoma cell skin cancer outside the head and neck area or completely resected stage I breast cancer, or completely resected in-situ non-muscular invasive bladder, cervix and/or uterine carcinomas.
19. Known contraindication to undergoing positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-D-glucose (18F-FDG-PET) scans, contrast-enhanced MRI or contrast-enhanced CT scans.
20. Known allergy to Debio 1143, cisplatin or any excipient known to be present in Debio1143 or in the placebo formulation.
21. Non-compensated or symptomatic liver cirrhosis (Child-Pugh score: B or C).
22. Any ongoing condition or disorder, before randomization, including drug(s) or alcohol abuse, which in the judgment of the Investigator would make the patient inappropriate for entry into the study or precluding his/her ability to comply with study procedures.
NCT
Promoteur
Coordonnateur
Informations relatives au promoteur
NCT :
NCT04459715
Promoteur :
Debiopharm International SA
Type de sponsor : Industriel
-
00000 HORS FRANCE

Coordonnateur :
Centre investigateur
Investigateur
TEC / ARC / IDE
État
MÀJ
Informations relatives aux investigateurs
Centre investigateur :
Centre Oscar Lambret - 3 Rue Frédéric Combemale - 59000 LILLE

Investigateur :
Docteur Cyril ABDEDDAIM

TEC / ARC / IDE :
Unité Intégrée de Recherche Clinique
investigation@
o-lambret.fr
03.20.29.59.35

Statut de l'essai : OUVERT

MAJ : 28/05/2021